Active, not recruitingPhase 4NCT05353829
Methotrexate in Patients with Early Rheumatoid Arthritis
Studying NON RARE IN EUROPE: Rheumatoid arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Region Västerbotten
- Principal Investigator
- Anna Södergren, MD PhDRegion Västerbotten
- Intervention
- Methotrexate(drug)
- Enrollment
- 212 target
- Eligibility
- 18-95 years · All sexes
- Timeline
- 2022 – 2026
Study locations (13)
- Region Sörmland, Eskilstuna, Sweden
- Region Dalarna, Falun, Sweden
- Region Gävleborg, Gävle, Sweden
- Region Norrbotten, Luleå, Sweden
- Reumatologsektionen Örebro universitetssjukhus, Öre, Sweden
- Region Jämtland Härjedalen, Östersund, Sweden
- Västra Götalandsregionen, Skövde, Sweden
- Akademiskt specialistcentrum, Stockholm, Sweden
- Danderyds sjukhus, Stockholm, Sweden
- Karolinska sjukhuset, Stockholm, Sweden
- Region Västernorrland, Sundsvall, Sweden
- Region Västerbotten, Umeå, Sweden
- Reumatologisk klinik, Västerås, Västerås, Sweden
Collaborators
Region Gävleborg · Umeå University · Uppsala University · County Council of Norrbotten, Sweden · Vastra Gotaland Region · Västernorrland County Council, Sweden · Dalarna County Council, Sweden · Karolinska University Hospital · Region Jämtland Härjedalen · Sormland County Council, Sweden · Region Stockholm
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05353829 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Rheumatoid arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07137598A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)Hoffmann-La Roche
- RECRUITINGPHASE1NCT07200596The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy SubjectsGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2NCT07100938A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid ArthritisBeiGene
- RECRUITINGPHASE1NCT07040930Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.Changchun GeneScience Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07089381Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.Ain Shams University
- RECRUITINGNANCT06693479Could a Feedback Device Help Manage Work-related Shoulder Disorders?Laval University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06475495Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisCharite University, Berlin, Germany
- RECRUITINGNCT07315997The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) StudyBrigham and Women's Hospital
See all trials for NON RARE IN EUROPE: Rheumatoid arthritis →